17 research outputs found
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
While research on T cell exhaustion in context of cancer particularly focuses on CD8C cytotoxic T cells, the
role of inhibitory receptors on CD4C T-helper cells have remained largely unexplored. TIGIT is a recently
identified inhibitory receptor on T cells and natural killer (NK) cells. In this study, we examined TIGIT
expression on T cell subsets from CLL patients. While we did not observe any differences in TIGIT expression
in CD8C T cells of healthy controls and CLL cells, we found an enrichment of TIGITC T cells in the CD4C T
cell compartment in CLL. Intriguingly, CLL patients with an advanced disease stage displayed elevated
numbers of CD4C TIGITC T cells compared to low risk patients. Autologous CLL-T cell co-culture assays
revealed that depleting CD4C TIGITC expressing T cells from co-cultures significantly decreased CLL viability.
Accordingly, a supportive effect of TIGITCCD4C T cells on CLL cells in vitro could be recapitulated by
blocking the interaction of TIGIT with its ligands using TIGIT-Fc molecules, which also impeded the T cell
specific production of CLL-prosurvival cytokines. Our data reveal that TIGITCCD4CT cells provide a
supportive microenvironment for CLL cells, representing a potential therapeutic target for CLL treatment
Neddylation inhibition upregulates PDâL1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149569/1/ijc32379_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149569/2/ijc32379-sup-0001-Supinfo.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149569/3/ijc32379.pd